Wednesday, January 30, 2013

Hyperglycemia in the Critically Ill: Consequences and Treatment


ABSTRACT

Laura E. Ridge

Hyperglycemia has long been recognized as a common occurrence in the critically ill, even without a history of diabetes. During times of stress or injury, nonnal glucose metabolism is altered because of changes in endocrine secretions and peripheral insulin resistance, resulting in stress hyperglycemia. Although hyperglycemia is a nonnal part of the stress response, it has recently been recognized to be associated with increased mortality and morbidity. Furthennore, insulin therapy has been shown to decrease mortality and improve other patient outcomes. However, many questions remain unanswered concerning the efficacy of insulin therapy. It is still unclear how tight glucose control should be and which patient types benefit from the treatment. More research is needed before insulin therapy can be widely used.

Hyperglycemia in Critically Ill Patients


ABSTRACT

Melissa Knieriem, DVM, DACVECC; Cynthia M. Otto, DVM, PhD, DACVECC; Douglass Macintire, DVM, MS, DACVIM, DACVECC

Hyperglycemia is common in critically ill humans. Recent clinical trials have shown a
significant reduction in morbidity and mortality rates with the use of intensive insulin therapy to maintain strict normoglycemia in critically ill patients. Hyperglycemia is associated with many detrimental effects, including reduced immune function, increased inflammation and coagulation, and modulation of the endothelium. Most of the evidence regarding the adverse effects of hyperglycemia is
derived from humans with diabetes, cardiac failure, or traumatic brain injury. In addition to its anabolic effects on metabolism, insulin has antiinflammatory properties.To define the potential risks and benefits of intensive insulin therapy in critically ill animals, prospective, randomized clinical trials are necessary. 

Full Text: CLICK HERE

Hyperglycemia in Critical Illness (A Review)

ABSTRACT

David Brealey, MB BS, BSc, Ph.D., FRCA, MRCP, and Mervyn Singer, MB BS, M.D., FRCP(Lon), FRCP(Edin)

Hyperglycemia is commonplace in the critically ill patient and is associated with worse outcomes. It occurs after severe stress (e.g., infection or injury) and results from a combination of increased secretion of catabolic hormones, increased hepatic gluconeogenesis, and resistance to the peripheral and hepatic actions of insulin. The use of carbohydrate-based feeds, glucose containing solutions, and drugs such as epinephrine may exacerbate the hyperglycemia. Mechanisms by which hyperglycemia cause harm are uncertain. Deranged osmolality and blood flow, intracellular acidosis, and enhanced superoxide production have all been implicated. The net result is derangement of endothelial, immune and coagulation function and an association with neuropathy and myopathy. These changes can be prevented, at least in part, by the use of insulin to maintain normoglycemia (J Diabetes Sci Technol 2009;3(6):1250-1260). 

Full Text: CLICK HERE

Hyperglycemia in Critical Care Illness

INTRODUCTION

Dr Neeru Gera,  Department of Endocrinology, Max Healthcare, New Delhi

Critically ill patients who require intensive care for more than five days carry 20% risk of death and significant morbidity. Hyperglycemia and insulin resistance are common in critical care settings, even observed in those without preexisting diabetes.
Newly detected hyperglycemia (admission or fasting blood glucose >126 mg/dl or two random blood glucose >200 mg/dl) in one study [1] was associated with higher in-hospital mortality (16%) than established diabetes (3%) or normal blood glucose (1.7%).The risk of in-hospital complications and ICU death increase by 3% for each 20 mg/dl increase in blood glucose above 100 mg/dl. 

Full Text: CLICK HERE

Evaluation of Nursing WOrk Effort and Perceptions about Blood Glucose Testing in Tight Glycemic Control


ABSTRACT

By Daleen Aragon, RN, PhD, CCRN.

Background Tight glycemic control is important in critically ill patients and involves insulin infusions and monitoring of blood glucose levels. Hourly measurements of blood glucose levels and adjustments of intravenous insulin doses require additional work by nurses.
Objectives To evaluate the nursing work incurred with and nursing perceptions about tight glycemic control and blood glucose monitoring.
Methods A variety of intensive care units were studied. Surveys were used to gain information about nurses’ perceptions. Time-in-motion observations were used to determine the time taken to measure blood glucose levels and adjust insulin doses. Results Nurses thought that tight glycemic control was important and that the work associated with it was substantial. Nurses thought that easier and automated forms of blood glucose monitoring are needed. They preferred using an arterial catheter to obtain blood samples to avoid excessive finger sticks. The total number of blood glucose measurements was 77 954. The mean time taken for hourly blood glucose monitoring and adjustment of insulin doses was 4.72 minutes. The estimated costs of time spent on glycemic control during a 1-year period were $182 488 for nurses’ salaries and $58 500 for supplies.
Conclusions Although most nurses endorse tight glycemic control, the work associated with it is burdensome and costly. Because up to 2 hours might be required for tight glycemic control for a single patient in a 24-hour period, the costs in time and money are high. Easier clinical methods for monitoring blood glucose levels are needed. (American Journal of Critical Care. 2006;15:370-377)

Full Text: CLICK HERE

Glycemic Control in Non Diabetic Critically Ill Patients


INTRODUCTION

Farnoosh Farrokhi, MD, Fellow of Endocrinology, Dawn Smiley, MD, Assistant Professor of Medicine, Guillermo E. Umpierrez, MD, Professor of Medicine

Hyperglycemia is a common and costly health care problem in hospitalized patients. In hospital hyperglycemia is defined as any glucose value >7.8 mmol/l (140 mg/dl). Hyperglycemia is present in 40% of critically ill patients and in up to 80% of patients after cardiac surgery, with w 80% of ICU patients with hyperglycemia having no history of diabetes prior to admission. The risk of  hospital complications relates to the severity of hyperglycemia, with a higher risk observed in patients without a history of diabetes compared to those with known diabetes. Improvement in
glycemic control reduces hospital complications and mortality; however, the ideal glycemic target has not been determined. A target glucose level between 7.8 and 10.0 mmol/l (140 and 180 mg/dl) is recommended for the majority of ICU patients. This
review aims to present updated recommendations for the inpatient management of hyperglycemia in critically ill patients with and without a history of diabetes. 
Best Practice & Research Clinical Endocrinology & Metabolism 25 (2011) 813–824.

Full Text: CLICK HERE

Effect of Hyperglycemia on Prognosis of Critically Ill Patients Des Not Differ Diabetics from Non diabetics


ABSTRACT

Yon Hee Shim, M.D., Chul Ho Chang, M.D., Jong Seok Lee, M.D., Seung Jung Kim, M.D., and Cheung Soo Shin, M.D.


Background: Hyperglycemia is common in critically ill patients, even in those without diabetes, and it is known to increase mortality in patients with or without diabetes in the settings of acute myocardial infarction or acute stroke. However, the clinical effects of admission hyperglycemia are uncertain, and no data is available that compares the prognosis in a heterogenous group of critically ill patients. The aim of this study was to evaluate the effect of hyperglycemia on prognosis in a heterogenous group of critically ill patients with or without diabetes.
Methods: The medical records of 858 consecutive adult patients admitted to a general intensive care unit (ICU) at a University Hospital over 21 months were reviewed. Patients with no records of blood glucose measurements and patients with normoglycemia during the first 3 days were excluded. The remaining 349 patients with hyperglycemia were divided into two groups according to a previous history of diabetes. Hyperglycemia was defined as a fasting blood glucose level of 140 mg/dl or more, or a random blood glucose level of 200 mg/dl or more on 2 or more determinations. The primary end-point of the study was ICU and in-hospital mortality, and its secondary end-point included length of stay in the ICU and hospital.
Results: There were no significant differences in ICU mortality (17.6/19.0%), in-hospital mortality (24.5/24.3%), ICU length of stay (6.6 ± 11.9/6.6 ± 10.4 days), and hospital length of stay (11.4 ± 29.0/12.8 ± 24.3 days) between diabetics and nondiabetics.
Conclusions: Our results indicate that the effects of hyperglycemia on the  prognosis of critically ill patients do not differ diabetics from nondiabetics. (Korean Journal Anesthesiol 2004; 47: S 10-S 13)

Full Text: CLICK HERE